AstraZeneca PLC - American Depositary Shares (NQ:AZN)

AMD Ignites the ‘Yotta-Scale’ Era: Unveiling the Instinct MI400 and Helios AI Infrastructure at CES 2026

January 08, 2026

LAS VEGAS — In a landmark keynote that has redefined the trajectory of high-performance computing, Advanced Micro Devices, Inc. (NASDAQ:AMD) Chair and CEO Dr. Lisa Su took the stage at CES 2026 to...

Via TokenRing AI

Topics Artificial Intelligence Economy

Rick R. Suarez appointed US President and Head of US BioPharmaceuticals Business Unit

January 08, 2026

From AstraZeneca

Momentum in Healthcare and Banking to Persist in 2026 as AstraZeneca and Citigroup Lead the Charge

January 02, 2026

As the global markets open for the first week of 2026, a clear narrative has emerged: the "recovery plays" of 2025 have officially transformed into the "expansion leaders" of the new year. Following a...

The 2026 Pharma Reset: How Industry Giants Are Navigating a New Era of Federal Price Controls

Topics Artificial Intelligence Economy Initial Public Offering

January 02, 2026

Yesterday marked the official commencement of the first-ever "Maximum Fair Prices" (MFPs) for ten of the most widely used drugs in the Medicare program, a direct result of the Inflation Reduction Act’s...

This rising star in quantum computing is a high-risk but potentially high-reward play.

Topics Economy Intellectual Property World Trade

Is IonQ Stock a Buy Now? ↗

December 30, 2025

MIchaelAaron Flicker is the co-author of "Hacking The Human Mind: The Behavioral Science Secrets Behind 17 of the World's Best Brands."

The Motley Fool Interviews MichaelAaron Flicker: Hacking the Human Mind ↗

December 29, 2025

AstraZeneca (AZN) shows a top technical rating and a high-quality consolidation pattern, signaling a potential breakout opportunity for technical traders.

AstraZeneca (NASDAQ:AZN) Shows Strong Technical Setup for Potential Breakout ↗

December 23, 2025

Via Chartmill

The Pfizer Pivot: A Deep-Dive into PFE’s 2025 Financial Recovery and Strategic Rebirth

December 22, 2025

As of today, December 22, 2025, Pfizer Inc. (NYSE: PFE) stands as a case study in corporate reinvention and the brutal reality of the post-pandemic "hangover." Once the darling of the global healthcare...

Via PredictStreet

Topics Economy Intellectual Property

ENHERTU® (fam-trastuzumab deruxtecan-nxki) granted Breakthrough Therapy Designation in the US as post-neoadjuvant therapy for patients with HER2-positive early breast cancer

December 22, 2025

From AstraZeneca

Trump Strikes New Drug-Price Deals With Roche, Novartis, Merck And Other Pharma Giants ↗

December 19, 2025

The deals expand the pricing program to most targeted drugmakers in exchange for temporary tariff relief.

The stocks listed here trade at forward earnings multiples of less than 18.

Topics Government World Trade

3 Absurdly Cheap Stocks You Can Buy For Less than $100 Right Now ↗

December 18, 2025

Novartis US Stock Rises On Reports Of White House Pricing Deal Due Friday — Roche Also In Talks ↗

December 17, 2025

The potential agreements would mark another step in Washington’s broader effort to reshape drug pricing.

ENHERTU® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab approved in the US as first new treatment in a decade for the 1st-line treatment of patients with HER2-positive metastatic breast cancer

Topics Government World Trade

December 15, 2025

From AstraZeneca

The New Year is shaping up to be an important one for this quantum computing stock.

What to Watch With IonQ Stock in 2026 ↗

December 11, 2025

AstraZeneca advances hematology and cell therapy ambition with largest-ever presence at ASH

Topics Artificial Intelligence

December 04, 2025

From AstraZeneca

Baxdrostat New Drug Application accepted under FDA Priority Review in the US for patients with hard-to-control hypertension

December 02, 2025

From AstraZeneca

The report states that the agreement between the U.S. and the U.K. is expected to be announced in the coming days.

US-UK Near Landmark Zero-Tariffs Pharma Deal, Announcement Expected Soon: Report ↗

December 01, 2025

Biotech Bull ETF Surges To 20-Month High: Analysts Say Medicare’s Drug-Pricing Blow Is Softer Than Feared ↗

Topics World Trade

November 27, 2025

Pricing updates for major therapies from Novo Nordisk, Teva, AbbVie, and others eased sector worries.

Novo Nordisk stock jumped Wednesday on a lighter-than-feared discount for Ozempic and Wegovy under the IRA.

Topics ETFs

Medicare Slashes Ozempic's Price Tag 71%; Why Novo Nordisk Rallied ↗

November 26, 2025

Via Investor's Business Daily

Topics Economy Government

IMFINZI® approved in the US as first and only perioperative immunotherapy for patients with early gastric and gastroesophageal cancers

November 26, 2025

From AstraZeneca

AstraZeneca PLC-SPONS ADR (NASDAQ:AZN) Passes Key Quality Investing Screen for Long-Term Growth ↗

November 25, 2025

AstraZeneca (AZN) is a top-quality stock for long-term investors, showing strong revenue growth, high profitability, and solid cash flow generation.

Via Chartmill

Why AstraZeneca Stock Bumped Higher Today ↗

November 21, 2025

The company is wasting little time figuring out the particulars of a sweeping capital investment program.

AstraZeneca plans $2 billion manufacturing investment in Maryland, supporting 2,600 jobs and catalyzing economic growth

Topics Artificial Intelligence

November 21, 2025

From AstraZeneca

AstraZeneca receives FDA approval for Koselugo to treat adults with NF1 and inoperable plexiform neurofibromas, backed by strong Phase 3 data.

FDA Approval Delivers Momentum For AstraZeneca's Rare Disease Portfolio ↗

November 20, 2025

Via Benzinga

Where Will IonQ Be in 10 Years? ↗

November 20, 2025

A lot can happen for this quantum computing leader over the next decade.

Johnson & Johnson said Monday it's putting up $3.05 billion to buy privately held cancer player Halda Therapeutics.

Johnson & Johnson Inks A $3.05 Billion Deal In Cancer Treatment ↗

November 17, 2025

Via Investor's Business Daily

IonQ (IONQ) Surges on Strong Revenue Outlook and Insider Confidence Amidst Quantum Computing Race

November 14, 2025

November 14, 2025 – Quantum computing pioneer IonQ (NYSE: IONQ) recently captured significant market attention, with its stock experiencing a notable 3.6% gain on November 5, 2025, driven by an...

The company inches closer to bringing a new drug to a very large addressable market.

Topics Intellectual Property

10 Health Care Stocks With Whale Alerts In Today's Session ↗

November 14, 2025

Via Benzinga

Why AstraZeneca Stock Was a Winner Today ↗

November 10, 2025